Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
A Prospective Open-Label Dose-Response Study to Correct Vitamin D Deficiency in Cirrhosis.
Journal: Digestive diseases and sciences
Published: July 12, 2023
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.
Journal: World journal of hepatology
Published: June 22, 2015
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Journal: Hepatology (Baltimore, Md.)
Published: March 25, 2014
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 20, 2013
Showing 1-4 of 4
Last Updated: 09/26/2026